

BELLVITGE BIOMEDICAL RESEARCH INSTITUTE

Director's report (2020)

Gabriel Capellá, IDIBELL Director

December 23rd, 2020

Index

- 1. Research indicators overview
- 2. Budget overview
- 3. COVID-19 crisis
- 4. Organizational changes
- 5. Scientific Advisory Board (SAB)
- 6. People Management
- 7. Good Practices in Research
- 8. Management issues

IDIBELL Institutional activities
 Strategic Plan follow-up




Research indicator's overview

Annual Report 2019

Scientific highlights


1260

Scientific articles in indexed journals



6803,237

Total Impact Factor (JCR 2018)



5,4

Average Impact Factor

Annual Report 2019

Activity



Internationalization indicators 2020





8,5% (12,3%) 2,3M€

Granted Projects (€)

International People

(International People in IDIBELL Payroll) 17

Granted projects (16% success ratio) **47%**



Aver. Intern.ERC projectsSpeakershosted at IDIBELL(External Seminars)

2020 Project Highlights: European Commission



ERC Consolidator Grant IDIBELL budget: 1.997.360 € PI: Carolina Florian



ERC Proof of Concept (PoC) IDIBELL budget: **150.000€** PI: Antonella Consiglio



MSCA-ITN-2020 (training NW) IDIBELL budget: 501.809 € PI: Mariona Graupera



SC1-BHC-06-2020 (collab.) IDIBELL budget: 87.000 € PI: José Luis Ferreiro

2020 Project Highlights: Other international



****** "<u>la Caixa</u>"

World Cancer Research IDIBELL budget: 189.500€ PI: Mariona Graupera

La Caixa Health Research IDIBELL budget: 652.046 € PI: Carolina Florian

#ERAPerMed

ERA-NET in Pres Medicine IDIBELL budget: 122.836 € PI: Ricard Mesia

2020 Project Highlights: International - Structure



Enriching lives, opening minds.

Inve**ST**igating **A**s **R**esearchers at **S**chool is a GAME (STARS GAME) Pressupost IDIBELL: **93.529 €**

Science Society

SWAFS. Paths to Successful Innovations (ISPAS) Pressupost IDIBELL: **22.962** €

2020 Project Highlights: National Calls



FEDER projectes singulars inst. d'infraestructures d'R+D Pressupost IDIBELL: **1.062.000 €**



Ajudes a plataformes de suport:

- Biobanc: **334.950 €**
- Innovació: **298.650 €**
- Assajos clínics: 412.500 €



Projecte d'especialització i competitivitat territorial PECT (RIS3CAT i FEDER) Total Budget: 3.135.512,12€ IDIBELL Budget: **1.923.221 €** (with 50% cofinancing)

2020 Project Highlights: National calls



RETOS / Generación conocimiento / Jovenes Investigadores (JIN) Total IDIBELL : **1.269.048 €** PIs: Casanovas, Capellá, Muñoz-Pinedo, Plass, Queralt i Vaquero (JIN) 6 projectes concedits dels 9 demanats



Aptamer-mediated delivery of siRNAs IDIBELL budget: **179.842 €** PI: Oscar Martínez-Tirado D'un total de 3 projectes concedits

2020 Project Highlights: National calls



AES 2020 (provisional resolution)

Projectes

21 projectes concedits 1 projecte DTS concedit

Ajuts RRHH

3 contractes intensificació
2 contractes Miguel Servet I
2 contractes Miguel Servet II
5 contractes Río Hortega
3 contracte Sara Borrell
4 contractes PFIS
2 Ajuts de mobilitat M-AES

TOTAL AES 2020:

2.801.404 €
2.785.904 €
15.500€

1.733.459€
90.000€
485.000€
202.500€
268.660€
241.794€
412.000€
33.505€

4.534.863 €




Malalties minoritàries Convocatòria 2020


7 projects coordinated Narváez, Pineda, Rivera, Pujana, Nunes, Torras i Casasnovas; Ventura (UB)

3 projects in collaboration Consiglio, Giorgetti i Padró

TOTAL La Marató 1.588.926 €

Innovation indicators overview





Spin-offs at IDIBELL



Development of customizable stents (Mitjançant 3D technology) and bioactive coatings (antibacterial and / or drug release).

Founding year: 2016



Development and commercialization of a new Kit for the early detection of Alzheimer's by means of an epigenetic analysis in blood, from measurements of methylcytosines in the mitochondrial DNA.

Founding year: 2017

XENOPAT

Preclinical services including Orthoxenograts[®] generation and access to OrthoXenoBank[®]. It also offers personalized treatment services to select the best cancer treatments.

Founding year: 2014



Development of a new molecule to prevent ultraresistant gram-negative nosocomial infections in Intensive Care Units (ICUs).

Founding year: 2018

New Spin Off Aptadel, SL



Aptadel: Multifunctional RNA molecules (chimera: aptamer+siRNA) to treat Ewing's Sarcoma and other sarcomas with high levels of EphA2 receptor.



- **Dr. Oscar Martínez Tirado:** Principal Investigator Chairman of the Board of Directors
- Alba Foundation (Venture Phil.): Rafa Perez Member of the Board of Directors
- Interim CEO + CSO



Patent: EP19382451.3 **Ownership**: IDIBELL, University of Iowa & Alba Foundation

Spin-Offs projects

AngioTheraGnostics (ATG)



AngioTheraGnostics: Development of a new drug to prevent antiangiogenic resistance accompanied by a diagnostic kit with a specific biomarker for the selection of those patients who will benefit from treatment.



Dr. Gabriela Jiménez: Project Manager (IDIBELL)
Dr. Oriol Casanovas: Principal Investigator (ICO-IDIBELL)
Dr. Ramon Salazar: Clinical oncologist (ICO-IDIBELL)

Purpose Tx



Purpose Tx: New anti-inflammatory biomolecule that acts selectively on inflammatory precursors and promotes tolerance for the treatment of autoimmune diseases: lupus nephritis, inflammatory bowel disease (IBD) and rheumatoid arthritis. The main indication would be IBD.




Dr. Josep Maria Aran: Principal Investigator (IDIBELL)
Dr. Anna Luque: Researcher (IDIBELL)
Dr. Jordi Guardiola: Clinical digestologist (HUB-IDIBELL)



Budget overview

- Evolution of funds raised
- Annual closings


Evolution of funds: Annual budget



27 26,7 27,1 26,9 28,8 28,2 27,8 28,1 ** Total Annual budget

* estimated; # after CMRB integration

Raised funds 2016-2020: competitive calls and innovation



Annual closings

	2016	2017	2018	2019	2020 estimated
a. INCOME	26.919.189,46	28.815.427,01	28.222.209,52	28.810.833,70	28.132.380,27
b. EXPENSES	-26.868.178,78	-28.668.951,34	-28.266.848,71	-28.910.109,70	-28.171.224,88
TOTAL	51.010,68	146.475,67	-44.639,19	-99.276,00	-38.844,61
VAT regularization	0,00	-476.704,34	-236.836,63	-50.630,80	0,00
PROFIT/LOSS	51.010,68	-330.228,67	-281.475,82	-149.906,80	-38.844,61



COVID-19 crisis

Pandemic management at IDIBELL



Crisis Committee 11 members Regular meetings



Crisis and lock-down easing protocols 7 versions

Catalan and English



Covid19 Mailbox 25 announcements 2,500 mails received



Company certificates

Adapted to each phase 875 elaborated

Pandemic management: Onsite work



PERSONAL PROTECTIVE EQUIPMENT (PPE)

Circulation and offices

To access and move around the facility and when working with more people, all personnel needs to wear a surgical mask.

Non-COVID research19

Usual instructions (lab coat, glasses and gloves) and surgical mask, in addition to the specifications of each room.


COVID19 research

Biosecurity level 2 spaces, FPP2 mask, waterproof and autoclavable coats, glasses, double gloves, cap & shoe covers.

Pandemic management: Prevention 6 100



467 Delivered masks People working onsite Procedures processed 1Nov-9Nov 124 25Sep-30 Oct PCR performed (29 positives) 24Ag-23Sep 28Jul-21Ag q 24Jun-27Jul Support psychological 3Jun-23Jun 236 12May-2Jun Capacities 1000 2000 3000 4000 5000 0 calculated



Project Highlights: COVID-19 calls

/Salut

3 projects from DGRIS: **614.505** € Drs J. Carratalà, X. Solanich i R. Máñez Total: 19 projects from 42 applications



3 projects from ISCIII: **515.256** € Drs J. Carratalà, O. Bestard i J. Bas Total: 129 projects from +1500 applications



ENVISION: Artificial intelligence & COVID-19 at ICUs Drs R. Mañez i M.J. Colomina IDIBELL budget: **115.000 €**

COVID-19 Projects



+25 Clinical Trials +80 +25 Research Projects

During the April-November period, more than 80 studies were carried out between basic research projects, clinical trials and observational studies.

Including collaborations with Mount Sinai Hospital or the Consortium "COVID Human Genetic Effort", among others

COVID-19 Research: Results

41 Collaborative research papers Lead research 27 Lead respapers

2 Fundraising campaigns 95k Euros received



Haematology Public Health







Organizational changes


- Organizational chart
- Research organization
- CRM[B] Merging

Organization chart

People and Strategy Directorate becomes the **Organization and People Directorate**.

Within this area, the **People Department** is created encompassing the Talent, People Management and Occupational Health Units.


Communications Unit and Fundraising Units merge and report directly to the General Directorate.




Organization chart

Regenerative Medicine Area is already on the institutional web and the rest of corporative materials.


The CMRB's scientific services are integrated into IDIBELL's research support units or new ones are created.



Research organization



2019



ISABEL RAMON FABREGAT SALAZAR (1) Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell)

> ESTEVE FERNANDEZ

(2) Epidemiology, Public Health, Cancer **Prevention and Palliative Care**

FRANCISCO

CIRUELA

EDUARD MONTANYA (5) Diabetes and Metabolism Program

VIRGINIA NUNES (6) Genes, Disease and Therapy



JORDI CARRATALÁ (9) Infectious disease and transplantation Program

ANGEL CEQUIER (7) Cardiovascular, Respiratory and Systemic Diseases and

JOSEP M. LLOP

(8) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention

cellular aging

(3) Neuroscience

NEURO

(4) Regenerative Medicine

REGENE.

MEDICINÉ

ANGEL RAYA

Calls for Program Coordinators 19-20



ONCOBELL – Appointment of R Salazar & I Fabregat co-coordinators (clinic&basic team). JM Piulats to take over R Salazar position

NEUROBELL	
NEUI	

NEUROBELL – Appointment of F Ciruela



EPIBELL– Appointment of E. Fernández

Changes in group leaders 19-20



Cardiovascular Diseases Dr Josep Comín (previous Dr Cequier)



Cellular and Molecular Neurobiology Dr Artur Llobet (previous Dr Solsona)



New IDIBELL Group at ONCOBELL Vascular-related diseases group Group leader <u>Dr Mariona Graupera</u> (former PI Dr Casanovas)



Hereditary Cancer Dr Conxi Lazaro new co-group leader with Dr Capellá



Nephrology and renal transplantation Dr Oriol Bestard new co-group leader with Dr JM Cruzado

CMR[B] integration

[INTRAMURAL]

Regenerative Medicine Area Regenerative Medicine Program



idibell.cat



[EXTRAMURAL]

Program for Translation of Clinical Regenerative Medicine of Catalonia



p-cmrc.cat



Regenerative Medicine Program



Program COORDINATOR

Angel Raya **Stem Cell Potency Research group** Angel Raya's Lab



Pluripotent Stem Cell Therapy Research group Anna Veiga's Lab



Gene Regulation of Cell Identity Research group Mireya Plass' Lab



Hematopoietic Stem Cell Biology and Leukemogenesis Alessandra Giorgetti's Lab



Stem Cell Aging Research group Carolina Florian's Lab



Cellular plasticity and regeneration Research group Jordi Guiu's Lab



Pancreas Regeneration Meritxell Rovira's Lab



P-CMR[C] organization





P-CMR[C] DIRECTOR Angel Raya



P-CMR[C] Co-Clinical DIRECTOR Antoni Bayés

Promoted by



P-CMR[C] ADVISORY BODY

- Representatives of the Catalan IIS
- Representatives of the Health Department from the Generalitat de Catalunya

(to guide the implementation of the P-CMR[C])



STEM CELL BANK Anna Veiga

P-CMR[C], Program for advancing the Clinical Translation of Regenerative Medicine of Catalonia



P-CMR[C]



Scientific Advisory Board (SAB)

IDIBELL SAB



Ana Maria Cuervo MD, PhD

Professor of Department of Developmental & Molecular Biology Albert Einstein College of Medicine



Ernest Arenas MD, PhD

Professor of Stem Cell Neurobiology Chairman of the Department of Medical Biochemistry and Biophysics Karolinska Institute



Paolo Gasparini MD, PhD

Professor of Istituto di Ricovero e Cura a Carattere Scientifico maternoinfantile Burlo Garofolo



Ana Aranda PhD

Professor of CSIC Departamento de Fisiopatología Endocrina y del Sistema Nervioso Inst. de investigaciones Biomédicas "Albert Sols"



Sonia Martínez PhD

Ex-Directora General de Innovación en Conselleria de Sanidad de la Xunta de Galicia



Lisardo Boscá PhD

Professor of CSIC Centro de Investigaciones Biomédicas Alberto Sols de Madrid



Robert Sackstein MD, PhD

Dean of the Herbert Wertheim College of Medicine at the Florida International University (FIU). Senior Vice-President of the FIU Academic Health Center

Research group evaluation: Timeline


19 groups	26 groups	21 groups
2017-2018	2018-2019	2019-2020
1 Research Program - Oncobell Program (19 groups)	 4 Research Programs Neurobell (9 groups) Epibell (4 groups) PEBC (9 groups) Genes, Disease & Therapy (4 groups) 	 4 Research Programs Diabetes & metabolism (3 groups) Cardiovascular, Respiratory, Systemic Diseases & cellular aging (4 groups) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention (9 groups) Infectious disease and transplantation (5 groups)



People Management

- HRS4R renovation in March 2021
- Active Tenure Tracks
- Professional career for researcher's implementation
- Training: Areté Program

HRS4R Action Plan (evaluation March 21')



Conclusions from the 2019 Survey

02. Recruitment and selection



- Poor knowledge and suitability of the evaluation and appraisal system
- Lack of programs and initiatives to foster mobility



Working conditions

03.

- Poor knowledge of the professional career structure
- The current work environment does not allow professional growth
- Poor representation on consultation and decisionmaking bodies
- Overall salary dissatisfaction
- Poor knowledge of the suggestions and appeals procedures and their suitability
- Poor communication between decision-making bodies and staff

04. Career development & training • Poor knowledge of the training plan and low level of training satisfaction



Current Tenure-track



Tenured in 2020







CARLES SORIANO XAVIER ALTAFAJ** STEPHANE FOURCADE ALESSANDRA GIORGETTI



**Left IDIBELL in summer 2020

ACTIVE TENURE-TRACK



Professional careers for researchers

96% of payroll PIs inside the professional career plan of IDIBELL

R3A

Julian Cerón Ana Maria Sola Núria Lloberas Oscar Martínez-Tirado Cristina Muñoz-Pinedo Purificación Muñoz Sara Larriba

R3B

Laura Valle Mariona Graupera

R4

Josep Maria Aran

Eric Duell

Virginia Nunes (UB-Professor) Ángel Raya (ICREA Researcher) Aurora Pujol (ICREA Researcher)

Anna Veiga Mercè Pérez Isabel Fabregat

Àngels Fabra

R4-E Emeritus George Thomas Sara Kozma

Areté website



Retorn a l'IDIBELL: Protocol de desconfinament en 4 etapes

424 students

100 Loor

100% online

Learn at your own pace



Recomendaciones de ergonomía para tu oficina en casa

70 students

NEW: Dirige a tu equipo a distancia 11 June 2020 12:00 - 14:00



Live webinar Scheduled activity C 2 h of training Beginner level Spanish

NEW: Microsoft Teams 17 June 2020 12:00 - 13:30



#IDIBELLconnect Webinars



Internal communication channels & brand Microsoft Yammer & IDIBELL Seminars weekly newsletter







IDIBELL Seminars Academic Year 2019 – 2020 (before March 2020)









Panel I: Opportunities and benefits of an academic career

Panel II: What you should know about jobs in the pharma and biotech industry

Panel III: What alt-careers are out there for me with a PhD?

2 Keynotes: Breaking the silos | Intellectual Property in life sciences 1 Workshop: Writing an effective CV and cover letter





7

Good Practices in Research

- Ombudsperson renewal & CIR committee
- Good Practices Research Guide Update
- Laboratory notebooks policy
- Animal facility accreditation



Ombudsperson renewal



Dr. Xavier Bosch IDIBELL (2015-2020)

Two **major issues** during 2015-2018 period:

- Conflictive relationship between with tenuretrack researcher and group leader
- Assessment of putative scientific fraud



Dr. Anna Veiga IDIBELL (June 2020-)

- Member of the Regenerative Medicine CEIC
- Director of the BCN Cell Lines Bank
- UB and UPF Professor
- Grifols S.A. Advisor (2008-2019)

Research Integrity Committee (CIR)

- **PRESIDENT = Anna Veiga**, Director Barcelona Stem Cell Bank, IDIBELL Researcher, Ombudpserson
- Francesc Xavier Bosch, Cancer Epidemiology Res. Program ICO, IDIBELL Researcher and former Ombusperson
- Josep Maria Cruzado, Head of the Nephrology Department, IDIBELL Researcher and UB Professor
- Rafael Máñez, Head of Intensive Internal Medicine Department, IDIBELL Researcher
- Jordi Trelis, Director of Care, Clinical Director of Palliative Care ICO
- Ernest Nadal, Medical Oncology Department ICO, IDIBELL Researcher
- Isabel Fabregat, ONCOBELL Program Coordinator, IDIBELL Researcher and UB Professor
- Concepció Soler IDIBELL Researcher and UB Professor
- Itziar de Lecuona, Deputy Director of the Bioethics and Law Observatory at the University of Barcelona, Member of the UNESCO Chair in Bioethics, UB Professor
- Enric Sospedra, Secretari CEIm Bellvitge HUB, Professor UB

Update of Good practices guide

Adaptation to the CERCA code (Novembre 2018)

INDEX (main updates)

- Research and biomedical research principles
- Research project design (Incorporation Data Management Plan and Impact Assessment Plan)
- Research with HUMANS (Obtaining biological samples, availability and conservation. Biobanking)
- Research with ANIMALS
- Security, health and environment
- Communication and Divulgation of results (CERCA acknowledgment and IDIBELL affiliation regulations; Open Access – UB Digital repository)
- Ombudsperson and Research Integrity Committee
- **Conflict of interest** (Procedure for the declaration of Col)
- Research misconduct (Procedure for suspected misconduct)

Laboratory notebooks policy

GOOD PRACTICE IN RESEARCH – CERCA CODE OF CONDUCT NOVEMBER 2018



The notebooks or documents are owned by the CERCA center where the work has been carried out.

IDIBELL LABORATORY NOTEBOOK

ACCURATE RECORD KEEPING



Free to all IDIBELL affiliates

- Preliminary record used to establish ownership of an invention and dates of discovery
- Experiments can be repeated and the results replicated and confirmed
- Repository of all primary data and results

Animal Facility



AN ACCREDITED ANIMAL CARE & USE PROGRAM SINCE 1971



The CEEA to evaluate the experimental procedures and detect and solve incidences. Report to be taken into consideration by the Directorate.

ſ	_	_	
Ŀ		-	
		-	
		-	
	-		

PECT-financed animal facility renewal has just finished. Entering in the final phase encompassing validation, cleaning and preparation for the future reopening



Reopening scheduled for February 2021



Management issues

- Digital transformation
- Data management

Digital transformation:

Disposal of paper warehouses

Destruction of current documents Data Protection Freeing up space

Digital signature

Official documentation: IDCat Unofficial documentation: unqualified signature

Documentation classification

Circuits / traceability Availability - Document Manager Systems audit ERP bidding

Teleworking

Law enforcement: Who, tools and resources needed New distribution of spaces

Work by objectives and evaluation of compliance

IDIBELL Data (Route map)

OneDrive Micrsosoft (dirty data)

- user@idibell.cat
- 1TB
- Private use of data
- No data specifications is needed



Dades sensible


ELECTRONIC NOTEBOOKS

IDIBELL Research Data Archive (hot data)

- FAIR Principles
- Metadata form is mandatory
- Private use (PI)
- Easy access (PI)
- Unlimited and free space for 2-3 y
- Allow data sharing with external researchers
- Security System guarantee (ISO)

Services offered:

- Data Management Plan (DMP)
- Data anonymization
- Data curation
- Sharing data with third parties &/or open repositories



- Data from IDIBELL Archive > 2-3y
- Private use
- Limited access
- Storage guarantee for 7-8 y
- Security system

Open Access Repository (DDUB, Llotja, EGA, etc.)

- FAIR Principles
- Data from IDIBELL Archive > 2-3y
- Data form publications
- Open Access data



9

IDIBELL Institutional activities

- SINERGIA 2020
- Salvem Vides '20

Sinergia 2020 (Virtual open house)

sinergia.l-h.cat



Festa de la Recerca i la Innovació en Salut de L'Hospitalet



New website & image

Digitization of the experience Audiovisual repository Thematic navigation

First 3 weeks

+4.000 website visits +11.000 pages viewed +3.500 video views +500h of video watched +300k social media reach

+ 11 live talks in streaming (28N)

"We save lives"

- First global fundraising campaign at IDIBELL
- Strategic objectives:



VISIBILITY IDIBELL brand Research programs



FUNDRAISING Crowdfunding Sponsors & philantropy





AWARENESS Research support Sense of belonging

2019: Oncobell program

\rightarrow cancer research

- Personlized medicine
- Immunotherapy
- Support to young talented researchers




2020: Neurobell program

- \rightarrow Neuroscience research
 - Cognitive impairment
 - Neurodegenerative diseases

SUSPENDED BECOUSE OF THE COVID-19



Strategic Plan Follow-up



				ЗТ 020	
				SL5	Organizatio
0				SL7	Financial su PECT II pen
SL1	Adscription procedure for local partners (CSI,		SL9	Deploy the	
	IMLCFC	2)		SL10	Organize Co
SL10	CIR nomination, Procedure for declaration of Col, and GRP review		SL13	Define the model for r	
SL11	Develop	ment (MPD	he Model of Professional) for Scientific Support (SS) and ort (MS): IDIBELL Evolve	SL14	Perform an
		SL1	Internal Call for Multidisciplinary	Research	Projects
		SL4	Research Data Management: Dat (hired), IDIBELL DMP guidelines, Laborato policy (pending)		
		SL8	Deploy the IDIBELL website		
		SL9	Welcome procedure & Staff Han	dbook	
	SL15 Define a policy for lab and office space us distribution and direct support to groups				and
		SL16 20	2 nd IDIBELL fundraising campaign	(Neurob	ell)
	20	20			

1T

2020

	QUICK WINS
Organization of Oncobell & Neurobell Symposia	2020
Financial support for Health Micro-Cluster (Fons Singulars; PECT II pending) Deploy the new intranet	Postponed due to Covid
Organize Co-creation activities within Patient associations and res Define the strategy for intensifications & compensation	search groups Not Accomplished Pending Accomplished
model for non-IDIBELL payroll: IDIBELL EVOLVE Perform an adscription campaign "IDIBELL reload" (IDIBELL anual	Retreat)

Deployment of Regenerative Medicine: New recruitments, Website, Eol &

Optimization of Trial's management: Process review, UICEC's ISO9001

Launching the PerMed and Adult Rare Disease Research Program

Projects

- and
- **Review IDIBELL Intellectual Property Regulations; Inauguration of the** SL6 **Industry Advisory Committee**

Benchmarking

SL2

SL3

SL4

SL5

4T 2020

- ≥ 70 % of publications signed as IDIBELL SL8
- Define and implement a (MD) PhD training program **SL12**
- **Complete Evaluation of all the research groups at IDIBELL SL14**

Increase the success ratio in International Grants





@IDIBELL_cat director@idibell.cat

Idibell.cat